Headlines about Regulus Therapeutics (NASDAQ:RGLS) have been trending somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regulus Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 48.0930284945814 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s analysis:
- Wedbush Analysts Lower Earnings Estimates for Regulus Therapeutics Inc (RGLS) (americanbankingnews.com)
- Wild stock to watch: Regulus Therapeutics Inc. (RGLS) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Regulus Therapeutics Inc. (RGLS) – Unusual Volume Spotlight – Wall Street Morning (wallstreetmorning.com)
- Leerink Swann Analysts Boost Earnings Estimates for Regulus Therapeutics Inc (RGLS) (americanbankingnews.com)
Regulus Therapeutics (RGLS) traded up $0.01 during trading hours on Friday, reaching $0.84. The company’s stock had a trading volume of 341,788 shares, compared to its average volume of 800,862. The firm has a market cap of $86.75, a P/E ratio of -0.76 and a beta of 1.72. Regulus Therapeutics has a 52-week low of $0.79 and a 52-week high of $1.95.
A number of research firms recently issued reports on RGLS. Leerink Swann began coverage on Regulus Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $2.00 target price for the company. Zacks Investment Research cut Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 25th. BMO Capital Markets set a $1.00 price target on Regulus Therapeutics and gave the stock a “hold” rating in a research report on Thursday, March 8th. Chardan Capital reaffirmed a “neutral” rating on shares of Regulus Therapeutics in a research report on Tuesday, January 16th. Finally, Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Regulus Therapeutics in a research report on Monday, December 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $2.20.
TRADEMARK VIOLATION NOTICE: “Regulus Therapeutics (RGLS) Earns Daily Coverage Optimism Rating of 0.17” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/17/regulus-therapeutics-rgls-receiving-somewhat-favorable-media-coverage-report-finds/2001022.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.